Abstracts tagged "Administrative Data"

Abstract Number: 1022 • ACR Convergence 2020
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Lupus is a serious, multi-system autoimmune disease that affects young people. Mortality is increased by over 2-3 fold compared to the general population. Time-trends…
Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Victoria Furer¹, Clara Weil², Melanie Orin², Gabriel Chodick², Varda Shalev², Yonit Fisher Shoval³, Raanan Cohen³ and Ori Elkayam⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, ³Abbvie, Hod Hasharon, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…
Abstract Number: 1026 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
Estefania Gauto-Mariotti¹, Soumyasri Kambhatla² and Augustine Manadan³, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²John H Stroger Hospital of Cook County, Riverside, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 0556 • ACR Convergence 2020
Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures
Cristiano Moura¹, Jeffrey R Curtis², Denis Choquette³, Gilles Boire⁴, Vivian Bykerk⁵, Carter Thorne⁶, Walter Maksymowych⁷, Peter Lakatos¹, Larry Svenson⁸, Laura Targownik⁵, Waqqas Afif¹ and Sasha Bernatsky⁹, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Institut de Rhumatologie de Montréal, Montreal, Canada, ⁴Universite de Sherbrooke, Sherbrooke, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Ontario Rheumatology Association, Aurora, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸University of Alberta, Edmonton, Canada, ⁹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Biosimilar infliximab offers a potentially lower‐cost treatment option compared to its bio‐originator. However, uptake of biosimilars in general in North America has been slow.…
Abstract Number: 1028 • ACR Convergence 2020
Probabilistic Linkage of a Cohort of Individuals with Symptoms Suggestive of Early Spondyloarthritis and the French National Healthcare Database
Aya Ajrouche¹, Candice Estellat¹, Clementina Lopez-Medina², Anna Molto³, Adeline Ruyssen Witrand⁴, Pascal Claudepierre⁵, Florence Tubach⁶, Laure Gossec⁷ and Maxime Dougados⁸, ¹AP-HP, Hôpital Pitié-Salpêtrière, Département Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, équipe PEPITES, CIC 1901, F75013, Paris, France, Paris, France, ²Rheumatology Department, Cochin Hospital, Paris, Paris, France, ³Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ⁴Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France, ⁵Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, ⁶Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, ⁷Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ⁸Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: DESIR is the French cohort of patients with symptoms suggestive of early axial Spondyloarthritis (axSpA). Our objective was to enrich this cohort with claims…
Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Shirley Huang¹, Xintong Li², Joehl Nguyen², Jacob Robinson², Susan Hogan³, Vimal Derebail³ and Carolyn Thorpe², ¹University of North Carolina at Chapel Hill, Chapel Hill, ²University of North Carolina Eshelman School of Pharmacy, Chapel Hill, ³University of North Carolina Kidney Center, Chapel Hill
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Mwangi Murage¹, Nicole Princic², Julie Park², William Malatestinic¹, Baojin Zhu¹, Bilal Atiya¹, Scott Kern¹, Keri Stenger¹, Aubrey Sprabery¹ and Alexis Ogdie³, ¹Eli Lilly and Company, Indianapolis, IN, ²IBM Watson Health, Cambridge, MA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].